Palisade Bio, Inc. (NASDAQ:PALI – Get Rating)’s share price fell 2.5% on Tuesday . The stock traded as low as $0.39 and last traded at $0.39. 47,201 shares were traded during mid-day trading, a decline of 96% from the average session volume of 1,094,799 shares. The stock had previously closed at $0.40.
Palisade Bio Trading Up 4.9 %
The stock’s 50-day simple moving average is $0.48 and its 200-day simple moving average is $0.79. The stock has a market cap of $8.95 million, a price-to-earnings ratio of -0.13 and a beta of 1.66.
Palisade Bio (NASDAQ:PALI – Get Rating) last announced its earnings results on Friday, May 13th. The company reported ($0.26) earnings per share (EPS) for the quarter. On average, equities research analysts forecast that Palisade Bio, Inc. will post -0.57 earnings per share for the current year.
Institutional Trading of Palisade Bio
Palisade Bio Company Profile
Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery.
- Get a free copy of the StockNews.com research report on Palisade Bio (PALI)
- Ford Stock Rallies As EV Strategy Takes Center Stage
- Should High Yield Altria Be In Your Portfolio?
- Is Keurig-Dr. Pepper A Value Worth Buying?
- C3.AI Stock is a Bargain Enterprise Artificial Intelligence Game Changer
- Two High Yield ETF That Can Substitute For Index Funds
Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with MarketBeat.com's FREE daily email newsletter.